Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019
(firmenpresse) - Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019
Business news for the stock market
Martinsried/Munich (17.05.2019) - Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene''s DC vaccine during the annual congress of the European Hematology Association (EHA) taking place from 13 - 16 June in Amsterdam.
Medigene will present a poster on June 15 from 17:30-19:00 entitled "Interim Analysis of a WT-1 and PRAME ` Fast-DC´ vaccine shows safety as active immunotherapy for the prevention of AML relapse".
For the full abstract of the poster, please follow this link:
https://learningcenter.ehaweb.org/eha/2019/24th/266840/yngvar.flisand.interim.analysis.of.a.wt-1.and.prame.fast-dc.vaccine.shows.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dinterim+analysis%2Ba+wt-1 or http://tiny.cc/678s6y
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor(at)medigene.com). We will then delete your address from our distribution list.
(end)
emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 33 3301
e-mail: investor(at)medigene.com
website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Die Medigene AG ist ein börsennotiertes Biotechnologie-Unternehmen mit Hauptsitz in Martinsried bei München.
" alt="Corporate Update - Site Preparation in Washington State, Oroville Campus & Oregon Hemp Farm">
" alt="Liberty Defense Featured on WSB-TV">
Datum: 17.05.2019 - 01:47 Uhr
Sprache: Deutsch
News-ID 1549125
Anzahl Zeichen: 4287
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 1128 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
